Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML

被引：26

作者：

Boehm, Alexandra ^{[1
,2
]}

Mayerhofer, Matthias ^{[3
]}

Herndlhofer, Susanne ^{[1
]}

Knoebl, Paul ^{[1
]}

Sillaber, Christian ^{[1
]}

Sperr, Wolfgang R. ^{[1
]}

Jaeger, Ulrich ^{[1
]}

Valent, Peter ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria

[2] Med Univ Vienna, Bone Marrow Transplantat Unit, A-1090 Vienna, Austria

[3] Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2009年 / 20卷 / 08期

关键词：

AML; Chemotherapy resistance; Rapamycin; mTOR; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; MAMMALIAN TARGET; HEMATOLOGIC MALIGNANCIES; ANTILEUKEMIC ACTIVITY; DOSE CYTARABINE; CANCER-THERAPY; MTOR; INHIBITOR; GROWTH;

D O I：

10.1016/j.ejim.2009.09.007

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Background: The mammalian target of rapamycin (mTOR) has recently been identified as a potential target in acute myeloid leukemia (AML). Methods: We treated 5 patients with chemotherapy-refractory AML with the mTOR-inhibitor rapamycin at 2 mg per os daily for 14 days, with dose adjustment allowed to reach a target serum rapamycin concentration of 1020 ng/mL. Four of five patients received additional hydroxyurea at constant dose during treatment with rapamycin. Results: Two patients achieved a leukocyte response, in one of them, a prolonged response was seen. In the other patients, blast counts remained stable or increased during rapamycin therapy. We did not observe severe hematologic or non-hematologic side effects of rapamycin. Conclusion: Rapamycin at 2 mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti-leukemic effects in these patients. (C) 2009 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

引用

页码：775 / 778

页数：4

共 33 条

[1]

The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[2]

Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells [J].

Boehm, A. ;

Aichberger, K. J. ;

Mayerhofer, M. ;

Herrmann, H. ;

Florian, S. ;

Krauth, M. -T. ;

Derdak, S. ;

Samorapoompichit, P. ;

Sonneck, K. ;

Vales, A. ;

Gleixner, K. V. ;

Pickl, W. F. ;

Sperr, W. R. ;

Valent, P. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (05) :395-405

[3]

Treatment of AML in biological subgroups [J].

Buechner, T ;

Berdel, WE ;

Schoch, C ;

Haferlach, T ;

Serve, HL ;

Schnittger, S ;

Kern, W ;

Tchinda, J ;

Reichle, A ;

Staib, P ;

Ludwig, WD ;

Aul, C ;

Sauerland, MC ;

Heinecke, A ;

Woermann, B ;

Hiddemann, W .

HEMATOLOGY, 2005, 10 :281-285

[4]

In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia [J].

Calabro, Anthony ;

Tai, Julia ;

Allen, Steven L. ;

Budman, Daniel R. .

ANTI-CANCER DRUGS, 2008, 19 (07) :705-712

[5]

Acute myeloid leukaemia [J].

Estey, Elihu ;

Doehner, Hartmut .

LANCET, 2006, 368 (9550) :1894-1907

[6]

New drugs in acute myeloid leukemia. [J].

Giles F.J. .

Current Oncology Reports, 2002, 4 (5) :369-374

[7]

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, MAPkinase and p53 pathways [J].

Grandage, VL ;

Gale, RE ;

Linch, DC ;

Khwaja, A .

LEUKEMIA, 2005, 19 (04) :586-594

[8]

Haferlach Torsten, 2008, Hematology Am Soc Hematol Educ Program, P400, DOI 10.1182/asheducation-2008.1.400

[9]

HARNDEN DG, 1981, CYTOGENET CELL GENET, V31, P5

[10]

Targeting mTOR signaling for cancer therapy [J].

Huang, S ;

Houghton, PJ .

CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :371-377

← 1 2 3 4 →